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Abstract 19
20
Recently, the potential application of deferoxamine (DFO) in several iron dysregulation diseases 21
has been highlighted. However, DFO presents significant limitations in clinical use due to its poor 22
absorption in the gut and very short plasma half-life. To overcome these problems, the feasibility 23
of chitosan/alginate hydrogels as prolonged delivery systems of DFO was investigated. Hydrogel 24
alone or co-formulated with poly(D,L-lactide-co-glycolide) microspheres were prepared and 25
studied in-vitro. The influence of the preparation methods on the performance of composite 26
hydrogels on controlled DFO release was explored. Spray-dried microspheres based on poly(D,L-27
lactide-co-glycolide) were able to encapsulate DFO, a highly water soluble drug. Nevertheless, only 28
the composite hydrogels managed to provide sustained drug release. The inclusion of 29
microspheres into pre-formed chitosan/alginate hydrogel provided the most efficient delivery 30
system; the drug released from microspheres is strongly entrapped in the hydrogel network and 31
slowly released by diffusion.32
33
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1. Introduction 42
43
Iron is a redox active metal, essential for life and indispensable for several biological reactions 44
(Camaschella & Strati, 2010). Nevertheless, its excess is toxic due to the release of reactive oxygen 45
species (ROS) (Loh, Hadziahmetovic, & Dunaief, 2009; Camaschella & Strati, 2010; Pouillot, Polla, & 46
Polla, 2013). The hydroxyl radical is very reactive and can cause oxidative damage to various cell 47
components, including lipid membranes, DNA, and proteins, thereby causing cell damage (Loh et 48
al., 2009; Yamasaki & Sakaida, 2012).  49
Disruption of iron regulation plays a key role in the etiology of neurological disorders, cancer, 50
stroke, muscle diseases such as Duchenne’s muscular dystrophy, and ageing (Jomova & Valko, 51
2011; Pouillot et al., 2013). Iron overload in the cytoplasm of hepatocytes contributes to 52
hepatocellular damage and hepatocarcinogenesis (Yamasaki & Sakaida, 2012). In the skin, excess 53
iron combined with UV radiation exerts pro-oxidant effects (Pouillot et al., 2013). Furthermore, it 54
is hypothesized that iron may contribute to the pathogenesis of ocular diseases (Loh et al., 2009). 55
Iron chelators are currently being investigated for their benefit in limiting iron-induced oxidative 56
damage. The best known iron chelator in clinical use is deferoxamine (DFO, Desferal™) (Loh et al., 57
2009). DFO as mesylate salt is the treatment of choice for acute iron intoxication and chronic iron 58
overload due to transfusion-dependent anemia (Hua, Keep, Hoff, & Xi, 2008). Data to support DFO 59
use in other disorders associated with iron overload are growing. Several studies have shown the 60
beneficial effects of DFO in reducing skin necrosis (Angel et al., 1986; Weinstein, Maves, & 61
McCormack, 1989; Diaz, Freeman, Wilson, & Parker, 1992; Morris et al., 1993; Hom, Goding, Price, 62
Pernell, & Maisel, 2000). DFO appears to mitigate radiation-induced hypovascularity and improve 63
tissue elasticity in a rat model (Mericli et al., 2015). DFO can prevent liver injury and development 64
of preneoplastic lesions in rats (Sakaida, Hironaka, Uchida, & Okita, 1999; Jin, Terai, & Sakaida, 65
2007), and it was proposed as an anticancer agent for the therapy of advanced hepatocellular 66
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carcinoma (HCC) (Yamasaki, Terai, & Sakaida, 2011; Yamasaki & Sakaida, 2012). Over the past few 67
years, a variety of studies have been conducted on DFO demonstrating some positive effects on 68
fracture healing (Stewart, Goldstein, Eberhardt, Chu, & Gilbert, 2011; Felice et al., 2013; 69
Hertzberg, Holt, Graff, Gilbert, & Dahners, 2013; Zhang, Li, Deng, Deng, & Qiu, 2012; Farberg, 70
Sarhaddi, Donneys, Deshpande, & Buchman, 2014; Grewal, Keller, Weinhold, & Dahners, 2014). 71
Unfortunately, DFO has properties that significantly limit its usefulness in a clinical setting. 72
Administration of this drug is limited to the parenteral route due to its poor absorption in the gut. 73
Furthermore, DFO has a very short plasma half-life because of rapid renal excretion; thus, 74
repetitive or continuous subcutaneous infusions are necessary to maintain its effective 75
therapeutic levels (Allain et al., 1987; Camaschella and& Strati, 2010). These are associated with 76
toxic effects (Cappellini & Pattoneri, 2009). Furthermore, repeated injection of DFO at the bony 77
injury may not be practical or effective clinically (Hertzberg et al., 2013).In most studies DFO was 78
administered in solution ( Yamasaki et al., 2011; Yamasaki & Sakaida, 2012; Farberg et al., 2014; 79
Mericli et al.,2015), and to date, very few formulation strategies have been developed in order to 80
improve DFO biopharmaceutical properties: i) conjugation to hydroxyethyl starch (Hespan) 81
(Hallaway, Eaton, Panter, & Hedlund, 1989) or to hyperbranched polyglycerol (HPG) (Imran ul-haq 82
et al., 2013) for increasing plasma half-life; ii) formulation in nasal microparticulate delivery 83
systems to improve the nose to brain transport (Rassu et al., 2015); iii) loading in morselized beads 84
of calcium sulfate (Grewal et al., 2014) or in true bone ceramic scaffolds (Zhang et al., 2012) for 85
the treatment of bone defects.86
Hydrogels are widely used as debriding agents, moist dressings, components of pastes for wound 87
care, as well as ocular drug delivery carriers, and subcutaneous inserts. Furthermore, hydrogels 88
are able to both locally embolize the hepatic tumor and deliver drugs in a controlled manner 89
(Giunchedi et al., 2013 Salis et al., 2015). Tissue engineering is one of the most recent application 90
of hydrogels as space filling agents, delivery vehicles for bioactive substances or as three-91
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dimensional structures that organize cells and ensure the development of a required tissue (Caló 92
& Khutoryanskiy, 2015). Composite hydrogels are a co-formulation of particulate systems 93
incorporated into the hydrogel matrix forming “plum pudding” hydrogel networks (Hoare & 94
Kohane, 2008). Incorporating degradable micro- or nanoparticles loaded with a drug in the 95
hydrogel can further extend the possibilities for controlling drug delivery (Buwalda et al., 2014). 96
This can have the added benefits of reducing burst release commonly displayed in microsphere 97
formulations and can prevent microsphere displacement away from the site of action (Hoare & 98
Kohane, 2008).  99
In order for DFO therapy to progress to clinical treatment, methods of delivery, timing, and dosage 100
need to be considered and optimized (Stewart et al., 2011; Farberg et al., 2014.; Grewal et al., 101
2014). In this study, the feasibility of hydrogel as prolonged delivery systems of DFO, useful for 102
solving the criticalities common to several iron dysregulation diseases, was investigated. Physical 103
chitosan/alginate hydrogel was selected in order to obtain a carrier able to control the delivery of104
this drug to the target site, and at the same time, depending on the disease, to serve as structural 105
support (eg. on fracture healing) or embolic agent (eg. in the therapy of advanced hepatocellular 106
carcinoma. Finally, it should be reabsorbed after it has served its function. This system should be 107
entirely biocompatible and biodegradable, no toxic, injectable or implantable. The materials used 108
well correspond to the characteristic quality of the required drug delivery systems making alginate 109
and chitosan more suitable carriers than others. The advantages of chitosan/alginate hydrogel 110
alone or co-formulated with PLGA microparticles were evaluated in-vitro.111
112
113
2. Materials and Method  114
115
2.1 Materials  116
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117
Sodium alginate Protanal LF 120 L (batch: 907788; MW: 221 kDa; viscosity (1% sol): 93 cP; 118
Seaweed species: Lessonia nigrescens; FG: 0.41; FM: 0.59; FGG: 0.22; FGM: 0.19; FMM: 0.40; FGGM: 119
0.05; FMGM: 0.14; FGGG: 0.17; NG>1: 5.6 (data from Hartmann, Dentini, Draget, & Skjåk-Bræk, 2006) 120
was purchased from FMC BioPolymer, now FMC Health and Nutrition, Philadelphia, (USA). 121
Chitosan ChitoClear TM 1358 (deacetylation degree: 95%; viscosity (1% sol): 63 cP; MW: 103 kDa; 122
ash residue: 0.9% (according to the manufacturer's specifications)) was acquired from PRIMEX 123
EHF, Siglufjordur, Island. Poly(D,L-lactide-co-glycolide) (PLGA) RG502 (viscosity: 0.16-0.24 dl/g 124
(50:50), MW: 7,000-17,000), RG504 (viscosity: 0.45-0.60 dl/g, MW: 38,000-54,000), and125
deferoxamine mesylate salt (DFO) were purchased from Sigma-Aldrich, St. Louis, USA. All other 126
solvents and chemicals were of analytical grade.127
128
2.2 Hydrogel preparation 129
130
Unloaded hydrogel characterized by a molar ratio 1/1 between alginate and chitosan and 2.5% 131
(w/v) concentration of polymers, in the final volume, were prepared. Sodium alginate solution 132
(2.44% w/v) was made dissolving alginate powder in water with the aid of a magnetic stirrer at 133
room temperature. Separately, chitosan (2.75% w/v) was dissolved in hydrochloric acid solution 134
pH 0.7, under magnetic stirring. Then, 1.25 mL of chitosan solution was added to 3.75 mL alginate 135
solution (pH 7.0) and stirred vigorously in order to obtain the final pH of 3.0. Loaded hydrogels 136
were prepared by dissolving DFO (3 mg) in chitosan solution before mixing polymer solutions. 137
138
2.3 Microsphere preparation 139
140
Microspheres, composed by PLGA, hydrophobic polymer, and DFO, hydrophilic drug, were 141
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prepared by using the emulsification/spray drying method previously described (Gavini et al., 142
2004). After preliminary studies, the total solid (drug + polymer) concentrations of 4% w/v was 143
selected; drug to polymer ratios of 1:4 and 1:10 were considered. Table 1 lists the formulations 144
prepared. Briefly, w/o emulsion was prepared by dissolving DFO in water and PLGA in 25 mL of 145
dichloromethane. The aqueous solution was added dropwise to the organic one within 5 min, 146
under homogenization at 10,000 rpm (Ultra-Turrax T25 basic, IKA, Germany). The w/o emulsion 147
was then sprayed through the nozzle (0.7 mm) of a spray-dryer, co-current flow type (Buchi Mini 148
Spray Dryer B-191, Milano, Italy). The process conditions are shown in Table 1. The temperature of 149
emulsion was maintained at about 5 °C throughout the process. No phase separation during the 150
spray-drying process was observed in the emulsion, thus rendering unnecessary the use of 151
surfactants (Supplementary Fig. S1). Microspheres were collected and kept under vacuum for 48 h 152
at room temperature.153
Blank microspheres were produced as control by dissolving PLGA in dichloromethane. 154
155
Table 1. Microsphere formulations: composition and spray-dryer manufacturing parameters. 156
Mean diameter and d90/d10 ratio were also reported.157
Microspheres 
compositiona
Spray dryer parameters Particle size and 
distribution
Formulation
DFO
(g)
water
(mL)
Air In
(°C)
Air Out
(°C)
dmb
(µm)
d90/d10
502 - - 50 41 5.63±0.31 8.33
504 - - 50 41 8.19±2.09 15.95
D502 4 0.250 5 80 55 29.76±2.87 9.97
D504 4 0.250 5 80 51 65.43±5.59 8.74
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D502 10 0.100 1.5 50 39 18.21±3.20 8.62
D504 10 0.100 1.5 50 42 23.33±2.53 14.00
aDrug to polymer ratio of 1:4 and 1:10 were used; The following conditions were also used during 158
spray-drying: drying airflow, 31.3 m3/h; spraying airflow, 500 l/h; solution feed rate, 4.09 ± 0.05 159
ml/min. bMean±standard deviation, SD (n = 15).160
161
2.4 Composite hydrogel preparation 162
163
Composite hydrogels were prepared by combining the microspheres and the hydrogel. Two 164
methods were tested: 1) PLGA microspheres (30 mg) were added into the chitosan solution; which 165
was then loaded onto the alginate solution and stirred vigorously; 2) the addition of microspheres 166
was performed after the formation of chitosan/alginate hydrogel. 167
168
2.5 Microsphere characterization 169
170
2.5.1 Yield of production 171
The yield of production was calculated as percentage of the weight of the final product with 172
respect to the total solid (drug and polymer) solubilized in the feed solutions.173
174
2.5.2 Particle size analysis using a suspension method 175
The particle size and particle size distribution of the microspheres were determined with a Coulter 176
LS 100Q Laser diffractometric equipment (Beckman Coulter Particle Characterization, Miami, 177
Florida). For particle size analysis using a suspension method, microspheres (2 mg) were 178
suspended in 1 mL of Tween 80 solution (0.1% w/v); the suspension was further diluted and 179
dispersed by vortexing for 10 min in case of formulation based on RG502 and vortexing for 10 min 180
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and sonication for 2 min in case of RG504. Values reported are the averages of three 181
determinations for five samples of each formulation (standard deviation, SD, n = 15).182
183
2.5.3 Powder particle size analysis  184
The particle size in the dry powder was measured by an HELOS Particle Size Analyser from 185
Sympatec GMbH, fitted with an Aspiros doser (pressure, 2.00 bar; vacuum, 36.00 mbar; feed 186
velocity; 25.00 mm/s). A lens able to detect particles in the size range  0.9 to 175 μm was fitted. 187
188
2.5.4 Drug Content  189
DFO loaded microspheres (15 mg) were dissolved in 2-4 mL dichloromethane with the aid of 190
magnetic stirring. The solution was then diluted with 40 mL of water and the organic phase was 191
evaporated using a rotavapor at 35°C before transferring the remaining aqueous solution into a 192
volumetric flask (50 mL) and analysed by HPLC as described below. One extraction was enough for 193
complete DFO recovery. 194
Loading efficiency (LE), as percentage, was calculated by using the following equation:  195
 eq 1 196
where DCA and DCT are the amount of drug loaded into the polymer matrix and the expected 197
theoretical value, respectively. DCA was calculated as previously reported (Rassu et al., 2014).198
199
2.5.5 Drug burst test  200
Microspheres (15 mg) were suspended in 50 mL of water, at either 37°C or at room temperature. 201
The samples were then vortexed for 10 sec before centrifugation (3,000 rpm for 5 min) and then 202
analysed by HPLC. 203
204
2.6 HPLC analysis of deferoxamine mesylate 205
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206
For the quantification of DFO in buffer samples, a Varian ProStar 210 with AutoSampler 410 and a 207
PDA photodiode array detector (Varian Inc Scientific Instruments, Walnut Creek, CA USA) was 208
employed. The chromatographic separation was performed as previously reported (Rassu et al., 209
2015). Briefly, separation was performed at room temperature on a C18 column with polar 210
endcapping (Phenomenex Synergi Hydro-RP 80A, 150 × 4.6 mm I.D. and 4 μm of particle size). 211
Twenty microliters of samples were directly injected into the column and eluted with a binary 212
mixture consisting of acetonitrile (pH 4.6 with 0.5 M H3PO4) and a 0.1M KH2PO4 (3.4 g/250mL), 120 213
mg/L (30 mg/250 mL) 1-eptane sulfonic acid sodium salt solution ratio 17:83 (v/v) adjusted to pH 214
4.6 by 0.5 M phosphoric acid. DFO was detected by UV at 210 nm wavelength. Concentrations of 215
analyte were calculated by interpolation of DFO standard curves.216
217
2.7 Hydrogel characterisation 218
219
2.7.1 Viscosity measurement 220
Viscosity of unloaded hydrogel as well as polymer solutions was measured, at room temperature, 221
by rotational viscometer (Alpha-L, Fungilab, Barcelona, Spain) at a constant rotation speed of 60 222
rpm or 100 rpm, respectively.223
224
2.7.2 Porosity measurement 225
The solvent replacement method was used to determine the porosity of the hydrogel samples 226
(Ranjha & Qureshi, 2014). Freeze-dried hydrogels (unloaded, loaded and composite) were 227
immersed in absolute ethanol overnight and weighed after blotting excess ethanol on the surface. 228
The porosity was calculated from the following equation: 229
  eq 2 230
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where M1 and M2 are the masses of the hydrogel before and after immersion in ethanol, 231
respectively, ρ is the density of absolute ethanol and V is the volume of the hydrogel.232
233
2.7.3 Water uptake and swelling 234
Hydrated and freeze-dried hydrogels (unloaded, loaded and composite) were weighed and fully 235
immersed in a sealed container with phosphate buffered saline (PBS; pH 7.4) for 24 h at 37°C 236
(Zang et al.2014) to study the water uptake (WU%) and swelling characteristics. Then, samples 237
were taken out, wiped with paper and weighed. The water uptake percentage was determined 238
gravimetrically using following equation:239
 eq 3 240
where M1 is the dry weight and M2 is the saturated weight. 241
Similarly, the swelling ratio was calculated from the volume of dry and saturated hydrogel. 242
243
2.7.4 Dynamic vapour absorption (DVS) studies  244
Dynamic vapour sorption (DVS) analysis of the freeze-dried hydrogels (unloaded, loaded and 245
composite) was carried out with a Surface Measurement Systems DVS Advantage instrument. 246
Using nitrogen as the carrier gas; the mass change of samples subjected to a changing water 247
vapour partial pressure at 25°C was recorded. The partial pressure was increased from 0 to 90% in 248
10% increments; the partial pressure was increased to the next step either after equilibrium or 249
after a maximum time of 360 min. A full adsorption/desorption cycle was performed; the data 250
collected were used to calculate the adsorption and desorption isotherms as well as the 251
hysteresis. The data were further analysed according to the following equation: 252
  eq 4 253
where Wp is the weight gain; Kp is the kinetic constant of water penetration into the composite 254
material; np is the exponent describing the mechanism of water penetration. 255
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256
2.7.5 Biodegradability 257
The weight loss of the composite hydrogels was monitored as a function of incubation time in PBS 258
(pH 7.4) at 37 °C for 24 days (Zang et al., 2014). Weights of the samples were measured at 10, 17 259
and 24 days of incubation, after freeze-drying. Degradation was determined by percentage of 260
weight loss (WL) using following equation:261
  eq 5 262
where W0 was the initial weight and WL was the weight after degradation. Each experiment was 263
repeated three times, and the value is reported as mean ± SD (n=3). No significant change in pH 264
was found during the test.265
266
2.8 Drug release studies  267
268
Release studies of DFO from microspheres, loaded and composite hydrogels were carried out. 269
Microspheres or hydrogels were put in 50 mL of PBS containing 0.01% Tween 80 and shaken at 80 270
rpm, 37°C for 10 days.271
At predetermined time points, 1 mL of medium was withdrawn and centrifuged at 13,000 rpm for 272
10 min, the supernatant was removed and stored at -20°C until HPLC analysis. Pellets eventually 273
obtained after centrifugation were resuspended in 1 mL PBS and poured back into the release 274
medium to restore the initial volume. Standard DFO solutions (60 mg/L) were stored in the same 275
conditions in order to check the possible degradation of DFO during the time.276
Release profiles were corrected to remove the degradation aspect and analysed with regards to 277
release kinetics and mechanism of release. The following equation describes the method used for 278
the corrections. Ftn is the corrected percentage release, Ft is the cumulative percentage release, t 279
is the time at which Ft level was taken.280
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  eq 6 281
The corrected data were then investigated for fit into various release models. Zero order is 282
demonstrated by plotting the corrected cumulative release fraction versus time. Zero order 283
describes the concentration-independent drug release rate from a formulation:284
  eq 7 285
First order release is described by plotting log cumulative drug fraction versus time and describes 286
concentration-dependent drug release from the system:287
  eq 8 288
The Hixson-Crowell cube root law describes the release from systems where there is a change in 289
surface area and diameter of particles (therefore applies to microsphere only formulations). As 290
described by equation 9, a straight line will confirm this type of release.291
  eq 9 292
The Korsmeyer – Peppas equation as shown in equation 10, describes the mechanism of drug 293
release. The release exponent can be used to characterise different release mechanisms (Arora, 294
Malik, Singh, Arora, & Rana, 2011).295
 eq 10 296
where Mt/M∞ is the fraction of drug released at time t, Kkp is the rate constant and n is the release 297
exponent.298
At the end of test, the microspheres, loaded and composite hydrogel were recovered, frozen at -299
80°C and freeze-dried for morphological examination. 300
301
2.9 Scanning electron microscope (SEM) studies  302
303
The morphology of microspheres and freeze-dried hydrogels was analysed by SEM. A Jeol JSM-304
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6060LV Scanning Electron Microscope was used and samples were coated with gold using a 305
Quorum Q 150RES spatter coater.306
307
2.10 Statistical Analysis  308
309
Data were analysed using the nonparametric Kruskal–Wallis test; individual differences were 310
evaluated using a post hoc Dunn's multiple comparison test (GraphPad Prism, version 6.02; 311
GraphPad Software Incorporated). When suitable, analysis of variance (ANOVA) followed by a 312
Tukey test was done.313
314
315
3. Results 316
317
3.1 Microsphere preparation and characterization 318
319
3.1.1 Yield of production 320
Microspheres were produced by spray–drying technique using RG502 and RG504 as polymers. 321
Spray–drying appears to be a suitable method for the preparation of unloaded and DFO loaded 322
microspheres, but with yield of production ranging from 34% to 67%. Loss of yield was due to 323
deposition in the spray-drying apparatus. This is a common problem with small drying chambers 324
and does not normally occur in industrial scale spray-drying due to the large cyclone area (Sosnik 325
& Seremeta, 2015).326
327
3.1.2 Particle size analysis 328
The particle size and particle size distribution of the microspheres were determined by analysing 329
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the powder in the dry state or in suspension. When measured in suspension (Table 1) there was 330
no significant difference in particle size between the two unloaded formulations (502 versus 504, 331
p=0.423), that differed only in molecular weight of the polymers used. The skewness in 502 is 332
slightly more to the right with almost double the leptokurtic value compared to 504. 502 also had333
smaller d90/d10 showing reduced distribution (Table 1). The loading of DFO in the polymer matrix 334
determined an increase of particles size regardless of the PLGA used mainly when the highest drug 335
amount was employed. In fact, the loaded D502 4 and D504 4 compared to the unloaded samples, 336
502 and 504, were significantly larger in size (p<0.05). Significant difference between particle sizes 337
of 502 versus D502 10 and 504 versus D504 10 were also observed (p>0.05) (Table 1). Both 338
unloaded and loaded samples were skewed to the right with leptokurtic properties. 339
The increase in particle size of all 504 formulations can be attributed to the increase in water/DCM 340
ratio (p=0.0029) (Supplementary Fig. S2). The distribution also narrows with increasing water 341
content (d90/d10 = 15.95, 14.00 and 8.74). Less evident but significant is the change of size of 502 342
formulations according to the ratio drug polymer used (Table 1, p<0.05). 343
In order to observe whether an improvement in particle size distribution with reduced aggregation 344
was observed using a dry method, samples were analysed using this method as a qualitative 345
assessment. The mean particle size was mostly larger using the dry method (Supplementary Fig. 346
S3), which could indicate that sample preparation for the suspension method for 502, 504, D502 4 347
and D502 10 broke aggregates and reduced the average particle size. 348
In comparison of the two particle size analysis methods, it is evident that suspending the 349
microspheres in solution containing surfactant as well as vortexing and sonicating is beneficial in 350
reducing aggregation which is advantageous to creating a true distribution curve of particle sizes.351
352
3.1.3 Drug Content and drug burst release 353
In order to accurately determine drug loading efficiency and drug release of PLGA particles, the 354
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actual drug content of the microspheres was investigated as well as the burst release. Burst 355
release as a proportion of actual drug content will help to determine which formulation manages356
to sustain drug release. All loading efficiency (LE) were above 83% of theoretical values (Fig. 1). LE 357
depends on factors such as kind of PLGA and drug to polymer ratio. When 1:4 drug to polymer 358
ratio was used, LE increased if PLGA with high molecular weight was used (D502 4 versus D504 4 P 359
= 0.0068); no significant differences were observed when high concentration of polymer was used 360
(D502 10 versus D504 10 P > 0.05). The drug to polymer ratio affected the LE only in the case of 361
502 formulations (D502 4 versus D502 10 P = 0.0310). Higher molecular weight formulations 362
tended to have a significant reduction in burst release (D504 4 versus D504 10, P > 0.05). Fig. 1363
shows a significant difference between D502 4 and D504 4, D502 10 and D504 10 and between  364
D502 4 versus D502 10. Temperature did not significantly affect the burst test.365
366
367
Fig. 1. Loading efficiency (LE) of formulations and the percentage of DFO released during the burst 368
test. 369
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370
3.1.4 Microspheres morphology by (SEM)  371
The image of unloaded 502 microspheres in Fig. 2A and 2C concurs with the particle size 372
distribution profiles discussed above. The Fig. 2 shows not only the wide range of particle size  373
present in the formulations but it also provides evidence that agglomeration is the cause for 374
anomalous spikes that occur in the distribution graphs (Supplementary Fig. S2). In contrast, 504 375
presented less visible aggregation between the microspheres which is likely due to the higher glass 376
transition temperature of the polymer. Fig. 2 also shows the presence of fibrous polymer between 377
microspheres; this could be due to the difficulty in separating the longer strands of polymer for 378
incorporation in individual spheres during the preparation process. Studies found that increasing 379
the drying gas flow rate will reduce this fibrous formation and therefore increase efficiency due to 380
better separation in the cyclone (Sollohub, 2009). 381
504 microspheres also had a comparatively more textured surface than 502. As all other 382
manufacture and formulation parameters, apart from the molecular weight of the polymer, were 383
kept constant, it is hypothesised that the more amorphous nature of the RG502 allowed the 384
formation of a smoother surface.385
Regardless of the polymer used, unloaded microspheres appeared to have a better spherical 386
appearance compared to loaded microspheres (Fig. 2 A-D). The difference could be due to the use387
of water in the formulation of loaded microspheres, this could cause disruption during structural 388
formation (Freiberg & Zhu, 2004). On examination of the manufacturing parameters, the increase 389
in outlet temperature from unloaded batches to loaded batches could also contribute to the large 390
morphological change.391
The surface of loaded microspheres appeared to be smooth with pores and did not show presence 392
of crystallised drug on the surface. This opposes theories that indicate drug deposited on the 393
surface as the reason for the burst release observed. The filamentous appearance of 504 is still 394
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present in the loaded microspheres D504 10 (Fig. 2D). 395
Morphology of D504 10 was observed also after drug release studies. Samples analysed after 396
release tended to show more agglomerated and fused particles (Fig. 2E). This occurrence is 397
explained by the reduction in glass transition temperature and therefore the increase in rubbery 398
nature of the PLGA in the presence of water. The filamentous structures disappeared after 399
dissolution, possibly due to degradation. Pores are present in this formulation which alongside 400
microsphere collapsing is the primary cause for burst release. There is some evidence of the 401
presence of drug after dissolution, indicating there is good internalisation of the drug in the dry 402
microspheres (Fig. 2F).403
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404
Fig. 2. SEM pictures showing morphology of unloaded microspheres: 502 (A) and 504 (B), D502 10 405
(C) and D504 10 (D), chosen as example (magnification 4,000 ×). E and F pictures showing 406
morphology of D504 10 after drug release studies (magnification 1,000 × and 4000 ×, respectively).407
408
3.1.5 Drug release studies  409
Release studies of DFO from microspheres were carried out. Standard deferoxamine solutions (60 410
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mg/L) were stored in the same conditions in order to check the degradation of DFO in solution 411
during the time.412
Degradation of DFO over time was observed in DFO solution. Whereas D502 4 and D504 4 curves  413
displayed concomitant release and degradation and had no significant difference in gradient (1-414
250 h) when compared to the standard (Supplementary Fig. S4). The high initial release of the 415
microspheres (86% and 90%) indicated a burst release, followed by a negative correlation to the 416
same degree as the DFO standard indicative of drug degradation with time.417
In an attempt to reduce the burst release of the microspheres, an increase in the ratio of polymer 418
to drug was used as well as a reduction in water content in the preparation process. D504 10 419
shows a high initial release followed by non-significant difference in degradation gradient (Time 1-420
240 hours, p=0.11629) when compared to the DFO solution. 421
D502 10 was not tested because of the very high percentage of DFO released during the burst test. 422
Even though the release profile was similar, they could be the result of a different ratio of drug 423
being released and being degraded. In order to examine the release profile, data points were 424
corrected to remove the degradation aspect. Most microsphere batches on their own exhibited 425
very little correlation with any of the kinetic or mechanistic equations (R2<0.9). It was found that 426
D502 4 had strong correlation with first order (concentration dependent), Hixson-Crowell and 427
Korsmeyer-Peppas at 1-6 hours. The application of the Hixson-Crowell equation shows that there 428
is a change in surface area and diameter of particles in the time frame 1-6 hours and from the 429
close fit to the Korsmeyer-Peppas equation, it can be deduced that D502 4 releases the drug with 430
diffusion as the rate controlling factor (n < 0.45).431
432
3.2 Preparation of hydrogels and characterisation 433
434
Unloaded and DFO loaded hydrogels as well as composite hydrogel were prepared. The molar 435
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ratio 1/1 and pH of 3.0 were found to be critical to formation of alginate and chitosan hydrogel. 436
The gelation was immediate after vigorously stirring the chitosan and alginate solutions at room 437
temperature (Supplementary Fig. S5) .438
439
3.2.1 Viscosity measurement 440
The viscosity of alginate and chitosan solutions employed for hydrogel formation was 460.3 ±8.7 441
cP and 658.1 ± 59.1 cP, respectively. The viscosity of hydrogel was 10 fold higher (4470.1 ± 458.9 442
cP).443
444
3.2.2 Porosity measurement445
Porosity of unloaded, loaded and composite hydrogels was measured by the solvent replacement 446
method. Results demonstrate that the porosity of the system remains unchanged regardless the 447
presence of DFO and microspheres and the preparation method of composite hydrogel (p>0.05). 448
The porosity of unloaded and loaded hydrogels was 84.86 ± 4.23%, and 82.11 ± 7.32%449
respectively. D502 hydrogel produced by 2nd method, showed a porosity of 78.68 ± 2.00%. No 450
significant differences in porosity were found in case of other composite hydrogels.451
452
3.2.3 Water uptake and swelling 453
In order to study the water uptake (WU,%) and swelling characteristics, the weight and volume 454
variations of hydrated and freeze-dried hydrogels were measured (Table 2). Freeze-dried 455
hydrogels absorbed a considerable amount of water and the unloaded ones showed the highest 456
WU percentage. The presence of microspheres reduces the WU value compared with the 457
unloaded hydrogel (p<0.05). After water absorption, the hydrogels obtained have a bigger volume 458
than freeze-dried forms. In particular the hydrogels containing DFO showed a 54% volume 459
increase, a much higher value compared to any other  (p<0.05).460
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Table 2. Water uptake (WU, %) and swelling ratio (SW, %)of unloaded, loaded and composite 461
hydrogels both hydrated and freeze-dried.462
freeze-dried hydrated
Hydrogel WU (%) ± SD SW (%) WU (%) SW (%)
unloaded 2759.9 ± 246.9$ 3.6 ± 0.7* -16.9 ± 2.2$* -8.3 ± 2.8*
loaded 2379.2 ± 151.4 54.2 ± 6.7*§ -1.04 ± 1.5*§ -32.3 ± 3.0*§
D502 (2nd method) 1954.1 ± 139.8$ 16.1 ± 1.5§ 7.9 ± 0.2$§ -0.3 ± 3.7§
$ § * P< 0.05 463
464
When the test was performed with the hydrated hydrogel, no water absorption was observed. On 465
the contrary, weight loss was observed as well as volume contraction. As a consequence, negative 466
WU and SW values were obtained. As concerning the preparation method, the composite 467
hydrogel obtained by 1st method did not differ from loaded hydrogel. On the contrary, the468
composite hydrogel from the 2nd method absorbed smaller amount of water but did not change in469
volume.470
No significant differences in water uptake and swelling were observed when different 471
microspheres were incorporated.472
473
3.2.4 Dynamic vapour absorption (DVS) studies  474
Dynamic Vapour Sorption (DVS) studies describe the mechanism of water sorption by the gels. The 475
unloaded hydrogel (Fig. 3 A) showed a profile typical of bulk water absorption; the hysteresis is 476
due to the reversible and elastic swelling deformations caused by the introduction of water 477
molecules within the polymeric network. This hydrogel fits the type II model according to the 478
BDDT classification, indicative of a multilayer mechanism of absorption. Loaded and composite 479
hydrogels (Fig. 3B and C), presented a type III isotherm: this profile is generally observed when the 480
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interaction between vapour/surface and vapour/vapour are similar so only a few molecules of 481
vapour adsorb on the surface at low partial pressure followed by condensation when higher 482
humidity is reached. For all hydrogels, hysteresis was greatly reduced for RH values greater than 483
60%, indicating this value as a critical RH after which no further structure deformation is occurring.484
By applying the Korsmeyer-Peppas equation to the  plots of percentage water sorbed vs. time, the 485
mechanism of hydration can be further understood. By comparing the diffusion exponent, it is 486
evident that the unloaded hydrogel (np=1.018) presents a Case-II transport mechanism where the 487
rate limiting factor is relaxation and chain disentanglement. For all loaded hydrogels 488
(0.45<np<0.89) diffusion is controlled by a combination of Fickian diffusion and gel deformation.489
490
491
Fig. 3.  Isotherm curves for unloaded (A), loaded (B) and composite (C) hydrogels. 492
493
3.2.5 Hydrogels morphology by SEM  494
The morphology of the hydrogels was evaluated in order to observe their overall structural 495
characteristics, the presence of microspheres, the presence of the drug and also the changes after 496
drug release.497
The unloaded hydrogel (Fig. 4A) presented a layered structure, whereas porous appearance was 498
observed for the loaded hydrogel. Furthermore, crystals of DFO were evident on the structure of 499
the loaded hydrogel (Fig. 4B). 500
Observing the composite hydrogel prepared with the two methods, the included microspheres 501
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were clearly visible. Fig. 4C shows the composite hydrogel produced by the 1st method, chosen as 502
example; it can be seen that particles included in the gel showed integral spherical shape without 503
collapse phenomena. After dissolution, crystals were found in the hydrogel indicating that the 504
composite hydrogel is able to entrap the drug released from the microspheres further delaying its 505
release (Fig. 4D). Greater drug crystallisation on composite hydrogel obtained with the 2nd method 506
occurred. Microspheres are visible after dissolution too (Fig. 4D).507
508
509
Fig. 4. SEM pictures showing morphology of unloaded (A) and loaded (B) hydrogel (magnification 510
500 × and 1,000 ×). SEM pictures showing morphology of D502 10 composite hydrogel, produced 511
by 1st method, before (C) and after (D) drug release studies (magnification 100 × and 230 ×), 512
chosen as examples.513
514
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3.2.6 Drug release studies  515
Fig. 5 shows the release of DFO from loaded and composite hydrogels. Loaded chitosan/alginate 516
hydrogel was able to control the release of DFO incorporated: 46% of the drug was quickly 517
released within 1 h, the release continued gradually till reaching a plateau at 72% after 48 h. After 518
144 h, no statistical differences are observed between profiles of loaded hydrogel and standard 519
DFO solution. Data obtained are affected by the degradation process of DFO and therefore Fig 5 520
shows release profiles corrected and not corrected to account for the degradation. The release of 521
DFO from the composite hydrogels was affected by the method of incorporation of the522
microspheres. If microspheres were added into the chitosan solution before hydrogel formation, 523
the resulting hydrogel showed a DFO release profile superimposable to the loaded hydrogel (p > 524
0.05) during the first 48 h. Afterwards, the concentration of released DFO from the composite 525
hydrogel declined indicating degradation exceeding release.526
When microspheres were incorporated into the preformed hydrogel, a much more sustained 527
release profile was observed (Fig. 5): 4% of drug incorporated in the microspheres was released 528
within 1 h and no further release was observed until 216 h. The ability of this composite hydrogel 529
to provide a more sustained release was attested also by the higher amount of DFO observed by 530
SEM after dissolution test, as above described. 531
It must be kept in mind that the release profile of all systems is the result of two different 532
phenomena occurring at the same time: release and degradation. 533
In order to examine the release profile, data points were corrected to remove the degradation 534
aspect using  equation 6. The D502 10 composite hydrogel formulation prepared with the 1st535
method did not show a strong relationship with either zero or first order overall, however, there 536
was indication of a first order release (concentration dependent) after 48 hours. This hydrogel also 537
fits with Korsemeyer-Pappas to show Fickian diffusion as the mechanism of drug release (n < 0.45)538
(Table 3). 539
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D502 10 composite hydrogel obtained with the 2nd method did not fit strongly to either zero or 540
first order overall or at selected time intervals. Korsmeyer-Peppas in this composite hydrogel 541
shows overall Fickian diffusion as the mechanism of drug release (n < 0.45) (Table 3). 542
No statistical differences were observed regardless the microspheres formulation employed. 543
The different behaviour of the composite hydrogel, can be attributed to the diverse water uptake 544
and swelling capability. The hydrated hydrogel from 2nd method, indeed, absorbed water but did 545
not reduce in volume whereas the other formulations significantly decreased in volume loosing 546
water entrapped into the hydrogel network. As a consequence the drug dissolved in water is 547
released from the hydrogel.548
549
550
Fig. 5. DFO release from composite hydrogel with incorporated D502 10 prepared adding 551
microspheres into the chitosan solution before hydrogel formation (1st method) or at preformed 552
hydrogel (2nd method). Data corrected (dotted lines) and not corrected (continuous lines).553
554
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Table 3. Table showing significant R2 values for the release kinetics and mechanism of release 555
models for microspheres and composite hydrogels. R2 was taken for the whole experimental time 556
frame, from points at the beginning and towards the end of the dissolution duration.557
t (h) Zero Order First Order
Hixson-
Crowell
Korsmeyer-
Peppas
D502 4 1≤ t <240 0.0857 0.0727 0.1345 0.0465
1≤ t <6 0.969 0.9724 0.9581 0.9940
1≤ t <24 0.4785 0.483 0.4651 0.8401
48≤ t <240 0.6221 0.6165 0.6359 0.4182
D502 10 1st
method
1≤ t <216 0.8658 0.8474 - 0.9437
1≤ t <24 0.7934 0.78 - 0.9918
48≤ t <216 0.947 0.9477 - 0.9568
D502 10 2nd
method
1≤ t <216 0.7562 0.6873 - 0.9612
1≤ t <24 0.8017 0.7368 - 0.978
48≤ t <216 0.6816 0.7115 - 0.7183
558
3.2.5 Biodegradability 559
Since ionically crosslinked alginate hydrogels do not specifically degrade but undergo slow, 560
uncontrolled dissolution (Drury & Mooney, 2003), biodegradability in PBS (pH 7.4) at 37 °C was 561
studied. Supplementary Fig. S6 shows the percentage of degradation measured for the composite 562
hydrogel obtained with the 1st method, containing microspheres characterised by 1:10 drug-563
polymer ratio. At the end of the drug release studies, the hydrogel biodegraded by approximately 564
32-34% on the first day. No significant difference was observed regardless the kind of 565
microspheres included in the hydrogel (p>0.05) at each time point. Concerning D502 10 and D504 566
10 composite hydrogels, a significant increase of degradability was observed between 10 and 24567
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days (p < 0.05), reaching 53% and 49% respectively. 568
The biodegradability of chitosan/alginate hydrogel studied was independent of the preparation 569
method employed.570
571
572
4. Conclusion 573
574
In this work, we proposed a new application of physical chitosan/alginate hydrogel and PLGA 575
microspheres for the modified release of DFO, for which there is a therapeutic demand. These 576
formulations produced can represent one of the few formulative approaches of DFO exploited. 577
DFO, highly water soluble drug, can be encapsulated in biodegradable microspheres of PLGA;578
nevertheless, formulation into a composite hydrogel is necessary in order to obtain sustained drug 579
release: hydrogel is better capable to control the DFO release compared to PLGA microspheres 580
and thus absolutely necessary for achieving the prearranged aim; the composite  chitosan/alginate 581
hydrogel gave the most efficient delivery system. Furthermore, the preparation method affected582
the performance of the obtained systems, the DFO release from them and consequently the kind 583
of therapeutic application. As example, hydrogel prepared by the first method can be formed in 584
situ after injection of both solutions/suspension; on the other hand, the second method gives an 585
implantable hydrogel.586
In conclusion, disruption of iron regulation plays a key role in the etiology of several diseases 587
(neurological disorders, cancer, stroke, skin, muscle and bone diseases), which require different 588
approaches, methods and time of treatment. The prepared systems not only could solve the 589
criticalities common to several iron dysregulation diseases, but show versatility and usefulness 590
with regard to the disease and/or administration route. 591
592
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